Mirtazapin Sandoz (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Sandoz, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It treats major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine, marketed as Mirtazapin Sandoz, is used within the antidepressant drug class to manage depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves mood in adult patients. - Depressive episodes associated with major depressive disorder: alleviates symptoms during acute episodes. - Treatment‑resistant depression (adjunctive): may be considered when first‑line agents are insufficient.

Mirtazapin Sandoz may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Sedation or drowsiness. - Increased appetite and weight gain. - Dry mouth. - Constipation. - Dizziness. - Orthostatic hypotension.

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia. - Hepatic dysfunction or jaundice. - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome). - Suicidal thoughts or behavior, especially early in treatment. - Serotonin syndrome when combined with other serotonergic agents. - Uncontrolled hypertension.

Before prescribing Mirtazapin Sandoz, clinicians should consider several safety precautions.

- Assess depression severity: confirm diagnosis before initiating therapy. - Monitor for suicidal thoughts: especially during early treatment or dose changes. - Use caution in hepatic impairment: dose adjustment may be required. - Elderly patients: increased risk of sedation and falls. - Avoid abrupt discontinuation: taper dose to minimise withdrawal symptoms. - Store at ambient temperature: keep in original packaging, protect from moisture.

Mirtazapin Sandoz can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis; discontinue MAOI at least 14 days before. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): enhanced sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine plasma levels. - Antihypertensive drugs: additive blood‑pressure‑lowering effect. - Anticholinergic agents: increased anticholinergic burden may worsen dry mouth and constipation.